Tag Archives | biotech stocks

Biotech Bull Market: Top ETFs Outperform Mutual Funds Over 2 Years

Can Healthcare/Biotechnology Funds Outperform ETFs in 2015? In January of 2013 we compared three of the most liquid life science ETFs to some of the top mutual funds in the sector. Review our 2013 summary but the conclusion at that time was that ETFs provided better returns than mutual funds over a five year period […]

Continue Reading 0

Tepid Rally Favors Large Caps: ABBV, GILD, RHHBY

Healthcare Stocks trail other sectors up 0.34%,  Energy  up 0.8%,  Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up 1.26%, Roche Holding (RHHBY) up 1.08% and Regeneron up 0.58%. Our large cap […]

Continue Reading 0

ETFs Outperformed Managed Biotechnology Funds YTD-FBT Is the Leader

2014 YTD- ETFs Outperformed Managed Funds In Biotech In the past managed life science funds outperformed ETFs but this has reversed in 2014. Fidelity’s flagship Select Biotechnology Portfolio (FBIOX) is up 10% YTD and 41.4% over one year, and 229.6% over 5 years.  The fund is concentrated in large cap and mid cap stocks; Gilead […]

Continue Reading 0

Green Day-Biotechs Are Running Again: ALKS, BIIB, GILD, VRTX

Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus stocks: ALKS up 2%, BIIB up […]

Continue Reading 0

Fidelity Select Biotechnology Fund (FBIOX) Outperforms Biotech ETFs YTD

Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology  investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the articles below and our comprehensive article from May 2011). […]

Continue Reading 0